Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by FarmerBetsyon Nov 22, 2023 10:53am
357 Views
Post# 35748387

Elliot, Ouch to the many haters could be a hate crime !

Elliot, Ouch to the many haters could be a hate crime !An Embarrassment to say moving forward, the IND delayed by what 5-6 months, then delay another 6 months and start testing 8 healthy volunteers, no Alzheimers patients! I'm sure that's a first in phase 1 Alzheimers clinical trials.
The real story is not about Promis entering Alzheimer clinical trials that's not going to happen. More clear than ever. With the stock at or near all time history lows from $115. to $1.30/ share, Promis's focus has not been on creating company shareholder value, rather SELECTIVE shareholder value for a select Boston group, BOD's and MPT.  Issuing share placements through (PIPE'S) at these low pricies.
Shut down the TSX, Social media, a confusing website, outdated information can be pointed out in all kinds of directions hardly inviting for attracting investor interest.
The last PIPE with Institutional Investors all previous players like JP Morgan, Bank of America, Morgan Stanley, Royal Bank etc, all shut out in the (PIPE) .  Three new companies got to participate with Spera funds an Iraeli company getting 1.8 million shares. I wonder who made these connections Gail, Eugene, Elliot? Just another Promis demostration of SELECTIVITY in PP's
<< Previous
Bullboard Posts
Next >>